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Induced Pluripotent Stem Cells for 
Clinical Use
Valérie Vanneaux
Abstract
The use of induced pluripotent stem cells (iPSCs) represents a great  promise 
in regenerative medicine. So far, several clinical trials are underway and 
 preliminary results are promising with the human embryonic stem cells, their 
non- reprogrammed counterparts. The experience of the clinical use of iPSC 
derivatives is extremely limited because of several major safety concerns, but many 
 technological advances in the field of iPSC generate high expectations in the near 
future to develop new clinical trials with an adapted level of patient safety. New 
guidelines and several recommendations are edited by researchers and regula-
tory agencies to guarantee the safety of the iPSC products in a clinical context for 
medical applications. In this chapter, we review the clinical trials with induced 
pluripotent stem cells and the main factors affecting the safe translation of iPSC to 
the clinic and how to overcome these issues by standardization and to control the 
quality of the clinical-grade iPSC products.
Keywords: clinical-grade induced pluripotent stem cells, regenerative medicine, 
clinical trials, quality control
1. Introduction
Since the discovery of induced pluripotent stem cells (iPSCs) by Yamanaka 
and Takahashi in 2006, many expectations have emerged, and iPSCs have 
opened up a world of possibilities for new cell-based therapies in regenerative 
medicine [1]. In the domain of pluripotent stem cells, iPSCs are considered as 
equivalent to embryonic stem cells (ESCs), because of two intrinsic key proper-
ties: their indefinite proliferative capacities while preserving pluripotency and 
their capacity to differentiate into all known cell types. However, in contrast 
to ESCs, iPSCs can be generated without any controversial ethical issues, 
thus favoring their use in clinical settings. Last but not least, in an autologous 
approach of cell-based therapy, by using the patient’s own cells as source for 
iPSC generation, one circumvents all the issues related to the immunological 
compatibility between the donor and receiver. This largely explains the tremen-
dous enthusiasm engendered by iPSC discovery in the sphere of regenerative 
medicine during the last decade. In this review article, we provide an overview of 
the launched clinical trials with iPSC and the ongoing efforts to understand the 
risk related to safety of iPSC-derived cells, highlighting some of the problems 
that have to be overcome.
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2. Clinical trials with iPSC
After over a decade of research on iPSC, and due to fast-track facilitating 
procedure in Japan, several clinical studies were launched. While the first clinical 
trial based on the human ESC started in 2010, taking advantage of the acquired 
extensive knowledge of ESC biology, despite their relatively recent discovery, 
the first clinical study based on the iPSC-derived retinal pigmented epithelium 
was authorized and conducted at the RIKEN Institute in Japan in 2014 [2]. A 
sheet of autologous iPSC-derived retinal cells were transplanted in a patient with 
eye-related macular degeneration (AMD). In 2015, the RIKEN Institute decided 
to suspend the study due to safety concerns on the cells of the second recruited 
patient [3]. Nonetheless, regarding the first transplanted patient, a 25-month 
follow-up revealed neither serious events, nor clinical signs of rejection. Moreover, 
the macular degeneration progress was delayed in the treated eye compared to the 
untreated eye. This result corroborated all the results obtained previously in the 
course of the ESC-based clinical studies, where no adverse events related to trans-
planted cells were observed. Still this problem induced a shift in the approach from 
patient-specific autologous to highly securized allogeneic iPSC lines. This study 
was resumed in 2017 and until now five patients with AMD have been treated with 
allogeneic iPSC-derived cells.
Since then, several clinical studies based on allogeneic iPSCs have been devel-
oped and approved. Until mid-2019, there have been nine ongoing clinical studies 
based on iPSC, mostly nationally approved in Japan, with four of them being 
approved in the first months of 2019, with indications including Parkinson’s disease, 
AMD, severe cardiac failure, aplastic anemia, spinal cord injury and corneal stem 
cell deficiency. Furthermore, two private companies—Cynata Therapeutics, an 
Australian stem cell and regenerative medicine company, and Fate Therapeutics, 
an American clinical-stage biopharmaceutical company—have developed a line of 
products based on allogeneic human iPSC-derived cells. In Australia and United 
Kingdom, Cynata Therapeutics just concluded a phase I study using CYP-001, an 
iPSC-derived mesenchymoangioblast precursor administered intravenously in 
15 patients with graft-versus-host disease (GVHD) occurring after an allogeneic 
hematopoietic stem cell transplant [4]. Currently, all patients treated so far have 
demonstrated at least a partial response, while no treatment-related serious adverse 
events or safety concerns have been observed. The product development activities 
of CYP-001 will be done in a phase II study in 2019 by Fujifilm in collaboration 
with Cynata Therapeutics. On its part, Fate Therapeutics received a first approval 
from Food and Drug Administration (FDA) in November 2018 to transplant an 
off-the-shelf iPSC-derived Natural Killer cell, FT-500, as cancer immunotherapy 
to treat solid tumors and for a second cell product derived from a genetically 
engineered iPSC, FT-516, in February 2019, for the treatment of relapsed/refrac-
tory hematologic malignancies. For the first product FT-500, all the three patients 
with advanced solid tumors have been treated with multiple doses of FT-500, 100 
million cells per dose, and it has been well tolerated with no dose-limiting toxicities 
or adverse events [5].
Even though the first clinical studies have already been started, technical 
advances in iPSC biology have revealed that several factors could affect their safety 
for a larger range of medical applications, and should be taken into account for 
short- and long-term follow-up of patients. Two of the major concerns related to 
iPSC-based products are their potential tumorigenicity and immunogenicity. The 
scientific community is still continuing to elucidate the biological mechanisms 
underlying iPSC’s immunogenicity and tumorigenicity and how to manage or 
overcome them.
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3. iPSC safety
3.1 Tumorigenicity
The potential risk of tumorigenicity to patients from both teratomas and 
malignant tumors could arise if transplanted cells are contaminated with undiffer-
entiated iPSC, or if transplanted cells have been genetically modified and become 
unstable during the in vitro production steps.
The major concern related to iPSC-based tumorigenicity is the reprogramming 
method. In the original cocktail of transcription factors developed by Yamanaka, 
somatic cells are transduced by retroviral vectors that become integrated into 
the genome of the host cells. Two of these factors—c-Myc and klf4—are potent 
oncogenes [6]. Subsequently, reports of tumorigenicity after transplantation 
of iPSC or iPSC-derived cells are not surprising. Thereby, teratoma formation 
could be induced by the undesired activation/suppression of essential host genes 
proximal to integration sites or by residual expression of reprogramming factors 
in the derived cells in animal model [7, 8]. With hindsight, there is evidence for 
the necessity to select a non-integrative method for reprogramming, a higher rate 
of genomic alterations occurring when human iPSCs are generated with viral 
vectors, compared to mRNA [7, 9]. Numerous studies, focused on the choice of 
reprogramming factors and methods of delivery, have developed various novel 
strategies to enhance the efficiency of reprogramming and reduce the potential risk 
of tumorigenicity. To circumvent this risk, human iPSCs have been generated by 
several “integration-free” methods, based on the use of viral vectors (adenoviral 
vectors and Sendai virus-based vectors) or non-viral vectors (piggyBac system, 
minicircle vector, and episomal vectors). Originally, the four transcription factors 
needed for complete cell reprograming were c-myc, klf4, oct4 and sox2 [1]. The pro-
tumorigenic transcription factor c-myc has been found to be unnecessary for the 
reprogramming process, but the overall efficiency is decreased without it. Several 
strategies have been developed with the use of different transcription factors and/
or replacement of c-myc, or the use of direct protein delivery and synthesized 
mRNA [10–12].
Furthermore, the tumorigenicity risk is often linked to the genetic instability of 
iPSC. Random genomic alterations are frequently observed in human iPSCs show-
ing their intrinsic instability, essentially due to the massive genome remodeling, 
and probably also resulting from various mechanisms such as replicative stress, 
reactivation of the telomerase and metabolism modification from the oxidative to 
the glycolytic state. Epigenetic modifications may also contribute to iPSC variation 
due to residual epigenetic memories of the starting cell type [13]. The incomplete 
resetting of the non-CpG methylation patterns during reprogramming leads to a 
biased differential potential in certain cell types depending on the donor cell source 
[14, 15]. However, it has been shown that their residual epigenetic memory dimin-
ishes with the in vitro expansion over a period of time [16, 17]. As just mentioned, 
the selection of the donor cell type is of importance. Many human somatic cell 
types have been successfully reprogrammed. However, even if the use of different 
transcription factors, delivery methods and culture conditions does not facilitate 
any comparison, it is well known that reprogramming efficiencies, kinetics and 
tumorigenicity vary between somatic cell types. Firstly, cell sources have to be 
permissive to avoid to turn to integrative methods and to the use of oncogenes. 
Some human, adult somatic cells, such as melanocytes, are known to naturally 
express endogenously reprogramming factors, for instance Sox 2, at sufficiently 
high levels [18, 19]. Moreover, some types of donor cells such as dermal fibroblasts 
and blood cells are easily accessible, but they might carry more mutational burdens 
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and chromosomal abnormalities, due to their frequent exposure to environmental 
stress factors, like ultraviolet rays, or due to the donor’s age, thereby leading to 
increased tumorigenicity, and significant safety problems [20, 21]. With all these 
considerations of cell variability and tumorigenic potential in mind, reflection on 
the generation of homogeneous cell source and banking emerged.
Many approaches have been evaluated to address the tumorigenicity challenge 
by eliminating the pluripotent cells of the final product such as small molecule, 
genetic approach to introduce a suicide gene; miRNA switch; antibodies targeting 
a surface-specific antigen; phototoxic approach; live detection and quantification 
of the residual human iPSC [22]. For the suicide gene approach, the most widely 
used gene is herpes simplex virus thymidine kinase (HSV-TK) that phosphorylates 
ganciclovir (GCV) and induces apoptosis by inhibiting DNA synthesis. Many stud-
ies demonstrated its efficacy as safeguard to eliminate tumoral cells [23]. Until then, 
this genetic approach with an inducible suicide system may remain not necessary 
enough to induce tumor elimination because of potential acquired resistance to 
GCV due to variability of insertion location sites and to the uncontrolled number 
of inserted transgene [24]. Another study demonstrated the same mechanism 
of inducing apoptosis in 95% of iPSCs and iPSC-derived cells by transducing an 
inducible Caspase 9 [25]. Recently, with development of targeted genetic strate-
gies such as gene-editing, researchers try to identify the location of “genomic safe 
harbors” (GSH), corresponding to the safest permissive loci for transgenes’ inser-
tion [26]. The already known GSH candidates could be AAVS1 (adeno-associated 
virus integration site 1), CCR5 (chemokine CC motif receptor 5), human ROSA26 
and some extragenic loci. Recently, to predict the influence of gene integration 
on nearby genes, it has been suggested that the combination of several distinct 
approaches such as the analysis of the topologically associated domains of GSH 
candidates of chromosomes could reduce the risks associated with cell therapy 
[27]. Another targeted alternative, eliminating selectively residual pluripotent cells 
sparing precursors and differentiated cells, involves PluriSIns, pluripotent cells-
specific inhibitors [28]. Alternatively, antibody, lectin or miRNA-mediated removal 
undesired cells were developed to suppress the pluripotent stem cells from the final 
product [29]. Lastly, a novel methodology using synthetic microRNA switch is 
developed to improve the purity of the final product even if the cell surface markers 
are not available to tag the relevant cells [30, 31].
3.2 iPSC immunogenicity
The immunogenicity of differentiated cells derived from iPSC is of clinical 
significance. At the beginning, because of the use of the patient’s own cells, theo-
retically there is no risk of rejection after their transplantation. Some studies dem-
onstrated no immune rejection of autologous iPSC-derived cells, but an activated 
immune response after the use of allogeneic iPS derived cells. Contrarily, immune 
rejection has been observed after autologous transplantation of iPSC-derived cells, 
suggesting that in vitro operations could also impact on the immunogenicity of 
the iPSC [32]. Moreover, the immune response to undifferentiated iPSC is differ-
ent from their derivatives, emphasizing the need to perform similar comparative 
analyses in starting cell populations in order to predict immune tolerance after 
transplantation. Whereas autologous hiPSC-derived smooth muscle cells were 
highly immunogenic, autologous hiPSC-derived retinal pigment epithelial (RPE) 
cells were immune tolerated, suggesting a potential abnormal expression of some 
immunogenic antigens in smooth muscle cells [33]. These results demonstrated that 
the nature of the differentiated cells could trigger an immune response suggesting 
the importance of the differentiation protocol.
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As mentioned earlier, because of their genomic instability, generation, amplifi-
cation and differentiation of iPSC could induce a modified immune response of the 
iPSC in vivo. Concerning reprogramming, the RNA-based methods are relatively 
efficient and do not integrate in the genome, but they are also known to be highly 
immunogenic. Concerning cell type, it has been widely shown that iPSCs could be 
generated from a patient’s own cells including fat cells, nerve cells, skin fibroblasts, 
cuticle cells, fetal foreskin cells, B cells, T cells, peripheral blood mononuclear 
cells, umbilical cord mesenchymal cells, chorionic mesenchymal cells and amniotic 
mesenchymal cells. But, some studies showed that the genetic memory of the 
cellular immunogenicity is conserved after reprogramming and differentiation. 
So, the selection of donor cell type/origin is crucial. As an example, iPSCs derived 
from less immunogenic cells, such as umbilical cord mesenchymal cells, generated 
less immunogenic neural derivatives than those from skin fibroblasts-derived iPSCs 
[34]. Recently, several researchers showed the less immunogenic potential of some 
iPSC-derived cells as cartilage and retinal pigment epithelium cells when they are 
implanted in vivo, arguing that some cell types are less immunogenic and should be 
preferred for clinical settings [35, 36].
Recently, a novel approach of “Universal” iPSC was developed to address the 
difficulty of immunogenicity of allogeneic iPSCs. Hypoimmunogenicity of iPSC 
was induced by inactivation of major histocompatibility complex class I and II 
genes and overexpression of CD47 enabled them to escape to immune rejection in 
fully HLA-mismatched allogeneic recipients. This strategy allowed the long-term 
survival of the transplanted cells without the use of immunosuppression. However, 
overexpression of CD47 is associated with malignant transformation, leading to 
include some suicide strategies as a safety concern [37]. These immune escape 
approaches open the door to the clinical use of allogeneic iPSC-derived cell products 
without immune rejection concerns and complications. However, their complex 
production process including a combination of several transduction and gene-
editing operations could add many safety issues. Even though other vectors and 
gene-editing techniques [38, 39] could also be used to reduce the risks, the multiple 
genetic manipulations and additional expansions in culture require a reinforced 
control of the “Universal” iPSC quality for clinical settings.
4. iPSC for clinical use
4.1 Clinical-grade allogeneic iPSC line bank
The use of human iPSCs in medicinal applications requires the establishment of 
standardized and validated protocols that will allow large-scale, cost-effective cul-
tivation procedure, while maintaining their quality. Implementation of good manu-
facturing practice (GMP)-compliant protocols for the generation and maintenance 
of human iPSC lines is crucial to increase the application safety and to fulfill the 
regulatory requirements to obtain clinical trials’ approval. Many efforts to increase 
the overall iPSC stability, reproducibility and quality have been performed by (1) 
selecting the cell type that is easily accessible, less immunogenic, and permissive for 
reprogramming and presents the ability to be stored for longer periods of time; (2) 
improving reprogramming efficiency, which should be as high as possible without 
genomic integration-based delivery method and without using oncogene and (3) 
improving cultivation methods with xeno- and feeder-free products, with defined 
and scalable conditions for maintenance and differentiation of human iPSC such as 
automation, closed cell systems and validated protocols [40]. Moreover, selection of 
cell source is of importance. Demonstration of comparability, standardization and 
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validation of such systems is critical for iPSC-derived therapies. To circumvent and 
manage the safety risk of the iPSC for regenerative medicine, several groups worked 
at the early stage on the development of standardized clinical grade iPSC banks from 
allogeneic donors. Indeed, the use of highly defined iPSC as starting cells pres ents 
many advantages as overcoming the genetic variations inducing different immuno-
genicity, genetic instability, tumorigenicity, and differentiation outcomes. Moreover, 
generation of iPSC from each patient is costly and time-consuming. In this regard, 
several groups in the world have developed banking of allogeneic iPSC lines for 
clinical use with validated and standardized protocols. The possibility of creating 
off-the-shelf iPSC-based therapies has attracted not only academics but also indus-
trial groups as Lonzo and Cellular Dynamics International, a Fujifilm company.
iPSC banks can provide a cost-effective mass-production strategy. Several groups 
have developed iPSC banks from selected HLA donors trying to cover the majority 
of the population [41, 42]. The Center for iPSC Research and Application (CiRA), 
in Kyoto University, started the iPS Cell Stock for Regenerative Medicine in 2013. 
Initially, based on the limited diversity of the Japanese population, CiRA wanted to 
generate clinical-grade iPSCs from samples of peripheral blood and umbilical cord 
blood from healthy selected donors that would cover 90% of Japanese population 
with only 50 iPSC lines [43]. This strategy is valuable for countries such as Japan, but 
could be difficult to expand to the worldwide population. It has been evaluated that 
a multiethnic iPSC bank of the 100 most common HLA types in each population 
would cover only 78% of European individuals, 63% of Asians, 52% of Hispanics 
and 45% of African Americans [44]. This probabilistic model highlights the neces-
sity of a large-scale international collaboration for the constitution of haplobank of 
iPSC lines. Using HLA-homozygous donors limits the numbers of iPSC lines needed 
to cover a given population, but identification of the potential donors would need 
large screenings or the use of established data from cord blood banks. The potential 
development of “universal” iPSCs made of genetically modified cells offering an 
off-the-shelf product that is readily available could be an alternative to the iPSC 
bank using materials from HLA-homozygous donors. The “universal” iPSC could 
solve the problem of immune rejection profile of iPSC-derived cells by artificially 
expressing, for example, HLA molecule as HLA-E allowing iPSC-derived cells to 
escape T cell-mediated rejection and to be resistant to NK-cell lysis [37, 45].
Nevertheless, stochastic events potentially occurring during reprogramming, 
colony expansion, iPSC selection, differentiation, iPSC-derived cell expansion and 
purification, storage and transport could complicate efforts toward a standardized 
product. Consequently, it has to be taken into consideration that variation may exist 
within any iPSC bank, between iPSC and final product composed of iPSC-derived 
cells in the clinic. Such variability requires continual extensive genotypic, pheno-
typic and functional assessment and highlights the need of a global quality control 
confirming the iPSC and the iPSC-derived cells’ quality whatever the manufacturer, 
the reprogramming method or the cell donors.
4.2 Quality control of clinical-based iPSC
Given the high variability across iPSC lines and their differentiated derivatives 
in terms of their epigenetic status, tumorigenic and immunogenic potential, dif-
ferentiation capacity, batch variability and existence of heterogeneous populations 
and/or non-relevant cells such as contaminating cell, the clinical outcome of the cell 
replacement therapy, in terms of efficacy and safety with these iPSC-based prod-
ucts, highly relies on the acceptable quality and safety standards of these products. 
Because of dissimilarities between institutions on these criteria, agreement on the 
critical quality attributes (CQAs) of such lines and the assays that should be used 
7Induced Pluripotent Stem Cells for Clinical Use
DOI: http://dx.doi.org/10.5772/intechopen.88878
is required. The CQAs correspond to the chemical, physical and biological proper-
ties of the product. As well as the type of assay, they have to be defined within an 
appropriate limit, range or distribution to ensure quality and safety of the product. 
For cell therapy product and for clinical-grade iPSC, the CQAs include identity, 
microbiological sterility, genetic fidelity and stability, viability, characterization and 
potency. In the last few years, there was a common effort made on the banking and 
the quality control of the iPSC lines. After a series of workshop, adaptation to iPSC 
of the established recommendations and guidance realized by the International Stem 
Cell Banking Initiative (ISCBI) for human embryonic stem cell banking, has gener-
ated initial recommendations on the minimum dataset required to consider an iPSC 
line of clinical grade [46]. During these workshops, the researchers, industrial and 
regulation agencies pointed out the requirement of standardization and validation 
of process and quality and safety controls. For each criterion, one or several tests are 
required with regard to the recommended analytical methods. Global consensus rec-
ommends the performance of assays by accredited and licensed laboratories. When 
it is not available, in-house tests should be undertaken after validation and qualifica-
tion, and comparability with other laboratories should be performed if possible.
The first mandatory test is to validate the identity of the iPSC line with the short 
tandem repeat (STR) analysis to genotype the original cells, the iPSC seeds and the 
master cell bank to ascertain the absence of switch or cross contamination of several 
iPSC lines during generation or maintenance process. Due to the nature of the stem 
cell-based products, they cannot be sterilized. The assessment of the microbiologi-
cal sterility is of the highest importance and should be performed not only on the 
final product. This should include the mycoplasma, bacteriology and viral testing 
supplemented by endotoxins detection assay and should have a negative result. The 
genetic stability and fidelity of the iPSC lines should be evaluated by residual vector 
testing and karyotype. To eliminate the risk of potential cell transformation and 
the risk of malignancy development in patients, residual vector testing has to be ≤1 
plasmid copy per 100 cells in seed and master cell banks and the karyotype should 
be normal on more than 20 metaphases. So far, techniques with high precision 
such as single nucleotide polymorphism (SNP) and whole genome analysis or other 
genetic markers are not required but could be performed for information. To give an 
appropriate dosage of cells, viability should be >60%. Calculation of doubling time 
and detection of cell debris are not required but could provide useful information. 
To manage the risk associated with the presence of non-desired or spontaneously 
differentiated cells, iPSCs have to be characterized by the expression of a minimum 
of two markers from the standard human pluripotent stem cells panel (positive 
for Oct4, TRA-1-60, TRA-1-81, SSEA-3, SSEA-4, Sox2, Nanog). A combination of 
one intracellular and one extracellular marker should be used and should be >70%. 
Finally, for the potency assay, reflecting the biological activity of the cells, embry-
oid body formation or directed differentiation of monolayer cultures to produce 
cell types representative of all three embryonic germ layers is mandatory. The 
teratoma formation in severe combined immune-deficient (SCiD) mouse injection 
assay is not mandatory for the iPSC due to a reproducibility problem, high cost and 
non-ethical procedure. Molecular pluripotency assays such as mRNA array- and 
RNA-Seq-based gene expression assays could be kept for information if they are 
performed molecular pluripotency assays such as mRNA array- and RNA-Seq-
based gene expression assays could be for information but are not required. For the 
iPS-derived differentiated therapeutic products, the minimal criteria are mostly 
identical except for the phenotypical characterization, which should validate the 
absence of pluripotent stem cell markers, the expression of dif ferentiation markers 
unique to the therapeutic product and assess 100% purity of the therapeutic cellular 
product without any contaminating other lineage cell types.
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This consensus on CQA and minimum testing requirements for clinical-grade 
iPSC lines will evolve with the advances in scientific understanding and develop-
ment in technology and best practices. The Global Alliance for iPSC Therapies 
(GAiT), which facilitates the development of general clinical-grade iPSC standards 
by community engagement and consensus building to support the global applica-
tion of iPSC-derived cellular therapeutics, is in charge of the future evolution 
of the consensus on quality and safety standards required for a clinical-grade 
iPSC. Moreover, GAiT presents objectives to achieve consensus on donor selection 
and screening criteria and consent standards, which with future commercialization 
and global distribution also require ethical review.
5. Conclusion
It is quite remarkable that in just over 10 years, research using iPSC has led to sev-
eral clinical studies, with many more applications expected to follow. In few years, the 
iPSC-based therapies induced a switch to a mass production of clinical-grade iPSC for 
the benefit of a large population at affordable costs, with the generation of clinical-
grade iPSC banks, and with a stronger involvement of biopharmaceutical companies. 
This shift led to many efforts for the standardization of generation, maintenance and 
differentiation procedures, and for the establishment of quality and safety standards 
for the clinical-grade iPSC and their derivatives prior to transplantation to patients.
There are still a number of challenges that must be overcome for iPSCs to reach 
their full potential. The improvement of manufacturing procedures for a large-scale 
production would provide higher quality cells for clinical iPSC-based therapies. 
Quality and safety controls are also challenging. Predicting cancer risk based on 
sequence information is a formidable task, and failure to detect oncogenic muta-
tions is not necessarily a warrantor of the non-tumorigenicity of iPSC-based prod-
ucts, suggesting that recommendations should still evolve with scientific advances.
Due to their large potential in regenerative medicine, such as the generation of 
complex 3D structures, tissues or organs, more challenges in differentiation proto-
cols in 3D structures have to be overcome for the up-coming year, without compro-
mising quality and safety of iPSCs.
Conflict of interest
The authors declare no conflict of interest.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
9Induced Pluripotent Stem Cells for Clinical Use
DOI: http://dx.doi.org/10.5772/intechopen.88878
[1] Takahashi K, Yamanaka S. 
Induction of pluripotent stem cells 
from mouse embryonic and adult 
fibroblast cultures by defined factors. 
Cell. 2006;126:663-676. DOI: 10.1016/j.
cell.2006.07.024
[2] Eguizabal C, Aran B, Chuva 
de Sousa Lopes SM, Geens M, 
Heindryckx B, Panula S, et al. Two 
decades of embryonic stem cells: 
A historical overview. Human 
Reproduction Open. 2019;2019(1): 
1-17. DOI: 10.1093/hropen/hoy024. 
eCollection 2019
[3] Mandai M, Watanabe A, Kurimoto Y, 
Hirami Y, Morinaga C, Daimon T, et al. 
Autologous induced stem-cell-derived 
retinal cells for macular degeneration. 
The New England Journal of Medicine. 
2017;376:1038-1046. DOI: 10.1056/
NEJMc1706274
[4] Cynata Therapeutics 
[Internet]. 2019. Available 
from: https://www.cynata.com/
graftversushostdiseaseaftversushost 
disease [Accessed: 30 June 2019]
[5] Fate Therapeutics [Internet]. 2019. 
Available from: https://fatetherapeutics.
com/pipeline/immuno-oncology-
candidates/ft500 [Accessed: 30 June 
2019]
[6] Rossignol J, Crane AT, Fink KD, 
Dunbar GL. Will undifferentiated 
induced pluripotent stem cells ever have 
clinical utility? Journal of Stem Cell 
Research and Therapy. 2014;4:189
[7] Galat V, Galat Y, Perepitchka M, 
Jennings LJ, Iannaccone PM, Hendrix MJ. 
Transgene reactivation in induced 
pluripotent stem cell derivatives 
and reversion to pluripotency of 
induced pluripotent stem cell-derived 
mesenchymal stem cells. Stem Cells and 
Development. 2016;25(14):1060-1072. 
DOI: 10.1089/scd.2015.0366
[8] Nori S, Okada Y, Nishimura S, 
Sasaki T, Itakura G, Kobayashi Y, et al. 
Long-term safety issues of iPSC-based 
cell therapy in a spinal cord injury 
model: Oncogenic transformation with 
epithelial-mesenchymal transition. 
Stem Cell Reports. 2015;4:360-373. DOI: 
10.1016/j.stemcr.2015.01.006
[9] Griscelli F, Desterke C, Feraud O, 
Divers D, Oudrhiri N, Tosca L, et al. 
Genomic landscape analyses of 
reprogrammed cells using integrative 
and non-integrative methods reveal 
variable cancer-associated alterations. 
Oncotarget. 2019;10(28):2693-2708. 
DOI: 10.18632/oncotarget.26857
[10] Feng C, Jia YD, Zhao XY. 
Pluripotency of induced pluripotent 
stem cells. Genomics, Proteomics & 
Bioinformatics. 2013;11(5):299-303. 
DOI: 10.1016/j.gpb.2013.08.003
[11] Melton C, Judson R, Blelloch R. 
Opposing microRNA families regulate 
self-renewal in mouse embryonic stem 
cells. Nature. 2010;463(7281):621-626. 
DOI: 10.1038/nature08725
[12] Zhou H, Wu S, Joo JY, Zhu S, 
Han DW, Lin T, et al. Generation of 
induced pluripotent stem cells using 
recombinant proteins. Cell Stem 
Cell. 2009;4:381-384. DOI: 10.1016/j.
stem.2009.04.005
[13] Liang G, Zhang Y. Genetic and 
epigenetic variations in iPSCs: Potential 
causes and implications for application. 
Cell Stem Cell. 2013;13(2):149-159. DOI: 
10.1016/j.stem.2013.07.001
[14] Kim K, Doi A, Wen B, Ng K, 
Zhao R, Cahan P, et al. Epigenetic 
memory in induced pluripotent stem 
cells. Nature. 2010;467:285-290. DOI: 
10.1038/nature09342
[15] Polo JM, Liu S, Figueroa ME, 
Kulalert W, Eminli S, Tan KY, et al. Cell 
References
Update on Mesenchymal and Induced Pluripotent Stem Cells
10
type of origin influences the molecular 
and functional properties of mouse 
induced pluripotent stem cells. Nature 
Biotechnology. 2010;28:848-855. DOI: 
10.1038/nbt.1667
[16] Ghosh Z, Wilson KD, Wu Y, 
Hu S, Quertermous T, Wu JC. Persistent 
donor cell gene expression among 
human induced pluripotent stem cells 
contributes to differences with human 
embryonic stem cells. PLoS ONE. 
2010;5:e8975. DOI: 10.1371/journal.
pone.0008975
[17] Boland MJ, Nazor KL, Loring JF. 
Epigenetic regulation of pluripotency 
and differentiation. Circulation 
Research. 2014;115:311-324. DOI: 
10.1161/CIRCRESAHA.115.301517
[18] Utikal J, Maherali N, Kulalert W, 
Hochedlinger K. Sox2 is dispensable for 
the reprogramming of melanocytes and 
melanoma cells into induced pluripotent 
stem cells. Journal of Cell Science. 
2009;122:3502-3510. DOI: 10.1242/
jcs.054783
[19] Kim JB, Greber B, Arauzo-Bravo MJ, 
Meyer J, Park KI, Zaehres H, et al. 
Direct reprogramming of human 
neural stem cells by OCT4. Nature. 
2009;461:649-643. DOI: 10.1038/
nprot.2009.173
[20] Lo Sardo V, Ferguson W, 
Erikson GA, Topol EJ, Baldwin KK, 
Torkamani A. Influence of donor age on 
induced pluripotent stem cells. Nature 
Biotechnology. 2017;35(1):69-74. DOI: 
10.1038/nbt.3749
[21] Musunuru K, Sheikh F, Gupta RM, 
Houser SR, Maher KO, Milan DJ, 
et al. Induced pluripotent stem cells 
for cardiovascular disease modeling 
and precision medicine: A scientific 
statement from the American 
Heart Association. Circulation: 
Genomic and Precision Medicine. 
2018;11(1):1-30. DOI: 10.1161/
HCG.0000000000000043
[22] Jeong HC, Cho SJ, Lee MO, 
Cha HJ. Technical approaches to induce 
selective cell death of pluripotent 
stem cells. Cellular and Molecular Life 
Sciences. 2017;74(14):2601-2611. DOI: 
10.1007/s00018-017-2486-0
[23] Schuldiner M, Itskovitz-Eldor J, 
Benvenisty N. Selective ablation 
of human embryonic stem cells 
expressing a “suicide” gene. Stem 
Cells. 2003;21:257-265. DOI: 10.1634/
stemcells.21-3-257
[24] Kotini AG, de Stanchina E,  
Themeli M, Sadelain M, Papapetrou EP. 
Escape mutations, ganciclovir 
resistance, and teratoma formation 
in human iPSCs expressing an HSVtk 
suicide gene. Molecular Therapy—
Nucleic Acids. 2016;5:e284. DOI: 
10.1038/mtna.2015.57
[25] Itakura G, Kawabata S, Ando M, 
Nishiyama Y, Sugai K, Ozaki M, et al. 
Fail-safe system against potential 
tumorigenicity after transplantation 
of iPSC derivatives. Stem Cell Reports. 
2017;8:673-684. DOI: 10.1016/j.
stemcr.2017.02.003
[26] Sadelain M, Papapetrou EP, 
Bushman FD. Safe harbours for the 
integration of new DNA in the human 
genome. Nature Reviews. Cancer. 
2012;12:51-58. DOI: 10.1038/nrc3179
[27] Kinamura Y, Shofuda T, Higuchi Y, 
Nagamori I, Oda M, Nakamori M, 
et al. Human genomic safe harbors 
and the suicide gene-based safeguard 
system for iPSC-based cell therapy. 
Stem Cells Translational Medicine. 
2019;8(7):627-638. DOI: 10.1002/
sctm.18-0039
[28] Ben-David U, Biran A, Scaffidi P, 
Herold-Mende C, Boehringer M, 
Meshorer E, et al. Elimination of 
undifferentiated cancer cells by 
pluripotent stem cell inhibitors. Journal 
of Molecular Cell Biology. 2014;6:267-
269. DOI: 10.1093/jmcb/mju012
11
Induced Pluripotent Stem Cells for Clinical Use
DOI: http://dx.doi.org/10.5772/intechopen.88878
[29] Lynch CL, Altun G, Tran HT, 
Garitaonandia I, Slavin I, Loring JF, 
et al. Specific lectin biomarkers for 
isolation of human pluripotent stem 
cells identified through array-based 
glycomic analysis. Cell Research. 
2011;21:1551. DOI: 10.1038/cr.2011.148
[30] Miki K, Endo K, Takahashi S, 
Funakoshi S, Takei I, Katayama S, et al. 
Efficient detection and purification 
of cell populations using synthetic 
microRNA switches. Cell Stem Cell. 
2015;16:699-711. DOI: 10.1016/j.
stem.2015.04.005
[31] Parr CJC, Katayama S, Miki K, 
Kuang Y, Yoshida Y, Morizane A, et al. 
MicroRNA-302 switch to identify and 
eliminate undifferentiated human 
pluripotent stem cells. Scientific 
Reports. 2016;6:32532. DOI: 10.1038/
srep32532
[32] Zhao T, Zhang ZN, Rong Z, Xu Y. 
Immunogenicity of induced pluripotent 
stem cells. Nature. 2011;474(7350): 
212-215. DOI: 10.1038/nature10135
[33] Zhao T, Zhang ZN, Westenskow PD, 
Todorova D, Hu Z, Lin T, et al. 
Humanized mice reveal differential 
immunogenicity of cells derived from 
autologous induced pluripotent stem 
cells. Cell Stem Cell. 2015;17(3):353-359. 
DOI: 10.1016/j.stem.2015.07.021
[34] Liu S, Yuan M, Hou K, 
Zhang L, Zheng X, Zhao SX, et al. 
Immune characterization of 
mesenchymal stem cells in human 
umbilical cord Wharton’s jelly and 
derived cartilage cells. Cellular 
Immunology. 2012;278(1-2):35-44. 
DOI: 10.1016/j.cellimm.2012.06.010
[35] Nguyen D, Hägg DA, Forsman A, 
Ekholm J, Nimkingratana P, Brantsing C, 
et al. Cartilage tissue engineering by 
the 3D bioprinting of iPS cells in a 
nanocellulose/alginate Bioink. Scientific 
Reports. 2017;7(1):658. DOI: 10.1038/
s41598-017-00690-y
[36] Westenskow PD, Bucher F, Bravo S, 
Kurihara T, Feitelberg D, Paris LP, et al. 
iPSC-derived retinal pigment 
epithelium allografts do not elicit 
detrimental effects in rats: A follow-up 
study. Stem Cells International. 
2016;2016:8470263. DOI: 
10.1155/2016/8470263
[37] Deuse T, Hu X, Gravina A, 
Wang D, Tediashvili G, De C, et al. 
Hypoimmunogenic derivatives 
of induced pluripotent stem cells 
evade immune rejection in fully 
immunocompetent allogeneic recipients. 
Nature Biotechnology. 2019;37:252-258. 
DOI: 10.1038/s41587-019-0016-3
[38] Roy KR, Smith JD, Vonesch SC, 
Lin G, Tu CS, Lederer AR, et al. 
Multiplexed precision genome editing 
with trackable genomic barcodes 
in yeast. Nature Biotechnology. 
2018;36:512-520. DOI: 10.1038/
nbt.4137
[39] Strohkendl I, Saifuddin FA, 
Rybarski JR, Finkelstein IJ, Russell R. 
Kinetic basis for DNA target specificity 
of CRISPR-Cas12a. Molecular Cell. 
2018;71:816-824.e3. DOI: 10.1016/j.
molcel.2018.06.043
[40] Dakhore S, Nayer B, Hasegawa K. 
Human pluripotent stem cell culture: 
Current status, challenges, and 
advancement. Stem Cells International.  
2018;2018:7396905. DOI: 10.1155/ 
2018/7396905
[41] Okita K. iPS cells for 
transplantation. Current Opinion 
in Organ Transplantation. 
2011;16(1):96-100. DOI: 10.1097/MOT. 
0b013e32834252a2
[42] Taylor CJ, Peacock S, Chaudhry AN, 
Bradley JA, Bolton EM. Generating 
an iPSC bank for HLA-matched tissue 
transplantation based on known donor 
and recipient HLA types. Cell Stem 
Cell. 2012;11(2):147-152. DOI: 10.1016/j.
stem.2012.07.014
Update on Mesenchymal and Induced Pluripotent Stem Cells
12
[43] Tokunaga K, Nakatsuji N, 
Nakajima F. HLA-haplotype banking 
and iPS cells. Nature Biotechnology. 
2008;26(7):739-740. DOI: 10.1038/
nbt0708-739
[44] Gourraud P-A, Gilson L, Girard M, 
Peschanski M. The role of human 
leukocyte antigen matching in 
the development of multiethnic 
“haplobank” of induced pluripotent 
stem cell lines. Stem Cells. 
2012;30(2):180-186. DOI: 10.1002/
stem.772
[45] Gornalusse GG, Hirata RK, 
Funk SE. HLA-E-expressing pluripotent 
stem cells escape allogeneic responses 
and lysis by NK cells. Nature 
Biotechnology. 2017;35:765-772. DOI: 
10.1038/nbt.3860
[46] Sullivan S, Stacey GN, Akazawa C, 
Aoyama N, Baptista R, Bedford P, et al. 
Quality control guidelines for clinical-
grade human induced pluripotent 
stem cell lines. Regenerative Medicine. 
2018;13:859-866. DOI: 10.2217/
rme-2018-0095
